Abstract
Irinotecan, cisplatin, and nitrosoureas have a long history of use in brain tumors, with demonstrated efficacy in the adjuvant treatment of malignant gliomas. In the era of temozolomide with concurrent radiotherapy given as the standard of care, their use has shifted to treatment at progression or recurrence. Now with the widespread use of bevacizumab in the recurrent setting, irinotecan and other chemotherapies are seeing increased use in combination with bevacizumab and alone in the recurrent setting. The activity of these chemotherapeutic agents in brain tumors will likely ensure a place in the armamentarium of neuro-oncologists for many years.
| Original language | English |
|---|---|
| Pages (from-to) | 297-306 |
| Number of pages | 10 |
| Journal | Neurosurgery Clinics of North America |
| Volume | 23 |
| Issue number | 2 |
| DOIs | |
| State | Published - Apr 2012 |
Keywords
- BCNU
- CCNU
- Chemotherapy
- Cisplatin
- Glioblastoma
- Glioma
- Irinotecan
- Nitrosoureas
Fingerprint
Dive into the research topics of 'Alternative Chemotherapeutic Agents: Nitrosoureas, Cisplatin, Irinotecan'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver